Skip to content

Study · Animal study (in vivo) · mouse · 2021

8 results

Peptide Szeto‑Schiller 31 ameliorates doxorubicin‑induced cardiotoxicity by inhibiting the activation of the p38 MAPK signaling pathway.

Zhang L, Feng M, Wang X, Zhang H, Ding J, Cheng Z, Qian L

International journal of molecular medicine2 Mar 2021Cited by 30 (Europe PMC)

PMID33649779 (opens in a new tab)PMCIDPMC7914074 (opens in a new tab)DOI10.3892/ijmm.2021.4896 (opens in a new tab)PepBankPUB-33649779
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice given doxorubicin, SS31 attenuated the level of reactive oxygen species.

    In plain wordsIn mice given doxorubicin, SS31 lowered the level of harmful reactive oxygen molecules.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseROS level
    Study

    mousen: not reported in source

    Doxorubicin-induced cardiotoxicity (20 mg/kg cumulative dose)
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    attenuating the level of ROS
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In mice given doxorubicin, SS31 stabilized the mitochondrial membrane potential.

    In plain wordsIn mice given doxorubicin, SS31 helped keep the mitochondrial membrane potential stable.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential
    Study

    mousen: not reported in source

    Doxorubicin-induced cardiotoxicity (20 mg/kg cumulative dose)
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    stabilizing the mitochondrial membrane potential
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice given doxorubicin, SS31 ameliorated myocardial apoptosis.

    In plain wordsIn mice given doxorubicin, SS31 reduced heart cell death.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMyocardial apoptosis
    Study

    mousen: not reported in source

    Doxorubicin-induced cardiotoxicity (20 mg/kg cumulative dose)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ameliorating myocardial apoptosis
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice given doxorubicin, SS31 ameliorated fibrosis.

    In plain wordsIn mice given doxorubicin, SS31 reduced scarring of the heart.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMyocardial fibrosis
    Study

    mousen: not reported in source

    Doxorubicin-induced cardiotoxicity (20 mg/kg cumulative dose)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    as well as fibrosis following treatment with DOX.
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  5. 05LabIn vitro (cells)Efficacy outcome

    In H9c2 cells treated with doxorubicin, SS31 attenuated the level of reactive oxygen species.

    In plain wordsIn heart cells treated with doxorubicin, SS31 lowered the level of harmful reactive oxygen molecules.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseROS level
    Study

    n: not reported in source

    H9c2 cells incubated with 1 µM DOX for 24 h
    Outcome group
    Oxidative stress · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    attenuating the level of ROS
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  6. 06LabIn vitro (cells)Efficacy outcome

    In H9c2 cells treated with doxorubicin, SS31 stabilized the mitochondrial membrane potential.

    In plain wordsIn heart cells treated with doxorubicin, SS31 helped keep the mitochondrial membrane potential stable.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial membrane potential
    Study

    n: not reported in source

    H9c2 cells incubated with 1 µM DOX for 24 h
    Outcome group
    Mitochondrial function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    stabilizing the mitochondrial membrane potential
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  7. 07LabIn vitro (cells)Efficacy outcome

    In H9c2 cells treated with doxorubicin, SS31 ameliorated myocardial apoptosis.

    In plain wordsIn heart cells treated with doxorubicin, SS31 reduced heart cell death.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMyocardial apoptosis
    Study

    n: not reported in source

    H9c2 cells incubated with 1 µM DOX for 24 h
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ameliorating myocardial apoptosis
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).
  8. 08LabIn vitro (cells)Mechanism

    In H9c2 cells treated with doxorubicin, SS31 inhibited the p38 MAPK signaling pathway.

    In plain wordsIn heart cells treated with doxorubicin, SS31 reduced activity of the p38 MAPK signaling pathway.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Decreasep38 MAPK signaling pathway
    Study

    n: not reported in source

    H9c2 cells incubated with 1 µM DOX for 24 h
    Outcome group
    Receptor activity and mechanism · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    the p38 MAPK signaling pathway was inhibited by SS31 in DOX‑treated H9c2 cells
    1 context sentence
    Summary · context
    To explore the effects of SS31 in DOX‑induced cardiotoxicity, the present study first constructed DOX‑induced cardiotoxicity models, in which H9c2 cells were incubated with 1 µM DOX for 24 h and C57BL/6 mice were administered DOX (20 mg/kg cumulative dose).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.